Deepak Srivastava, MD, explores how cellular reprogramming offers new hope for treating heart disease. He highlights innovative strategies to regenerate damaged heart tissue by stimulating adult cardiomyocytes to divide and converting fibroblasts into heart-like cells. His team develops a nonviral delivery system using lipid nanoparticles and investigates the role of specific gene regulators in restoring heart function in animal models. Srivastava also discusses a potential oral therapy for aortic valve disease, driven by insights into cellular fate changes caused by NOTCH1 mutations and telomere shortening. Additionally, he reveals how trisomy 21 may trigger congenital heart defects by altering the identity of specialized heart cells. Through pioneering research in genetics and regenerative medicine, Srivastava demonstrates how understanding developmental biology can lead to transformative clinical advances. (#40447)